Contrasting Nyxoah (NASDAQ:NYXH) & KORU Medical Systems (NASDAQ:KRMD)

KORU Medical Systems (NASDAQ:KRMDGet Free Report) and Nyxoah (NASDAQ:NYXHGet Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Risk & Volatility

KORU Medical Systems has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for KORU Medical Systems and Nyxoah, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KORU Medical Systems 1 1 3 1 2.67
Nyxoah 1 0 3 1 2.80

KORU Medical Systems presently has a consensus price target of $6.13, indicating a potential upside of 32.86%. Nyxoah has a consensus price target of $11.67, indicating a potential upside of 234.29%. Given Nyxoah’s stronger consensus rating and higher possible upside, analysts clearly believe Nyxoah is more favorable than KORU Medical Systems.

Earnings and Valuation

This table compares KORU Medical Systems and Nyxoah”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
KORU Medical Systems $33.65 million 6.35 -$6.07 million ($0.08) -57.63
Nyxoah $4.89 million 24.31 -$64.10 million ($2.49) -1.40

KORU Medical Systems has higher revenue and earnings than Nyxoah. KORU Medical Systems is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares KORU Medical Systems and Nyxoah’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
KORU Medical Systems -9.49% -22.43% -13.86%
Nyxoah -1,457.97% -101.99% -66.74%

Institutional and Insider Ownership

58.6% of KORU Medical Systems shares are held by institutional investors. 20.6% of KORU Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

KORU Medical Systems beats Nyxoah on 8 of the 13 factors compared between the two stocks.

About KORU Medical Systems

(Get Free Report)

KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.

About Nyxoah

(Get Free Report)

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Receive News & Ratings for KORU Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KORU Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.